blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3092232

EP3092232 - HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS FOR USE AGAINST CANCER AND VIRAL INFECTIONS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  13.01.2023
Database last updated on 05.07.2024
FormerThe patent has been granted
Status updated on  04.02.2022
FormerGrant of patent is intended
Status updated on  08.08.2021
FormerExamination is in progress
Status updated on  07.07.2021
FormerGrant of patent is intended
Status updated on  23.03.2021
FormerExamination is in progress
Status updated on  12.05.2017
Most recent event   Tooltip14.06.2024Lapse of the patent in a contracting state
New state(s): MC		published on 17.07.2024 [2024/29]
Applicant(s)For all designated states
Sagimet Biosciences Inc.
155 Bovet Rd 303
San Mateo, CA 94402 / US
[2020/35]
Former [2020/01]For all designated states
3-V Biosciences, Inc.
155 Bovet Rd 303
San Mateo CA 94402 / US
Former [2017/03]For all designated states
3-V Biosciences, Inc.
3715 Haven Ave., Suite 220
Menlo Park, CA 94025 / US
Former [2016/46]For all designated states
3-V Biosciences, Inc.
1050 Hamilton Court
Menlo Park, CA 94025 / US
Inventor(s)01 / WAGMAN, Allan S.
c/o Sagimet Biosciences Inc.
155 Bovet Rd 303
San Mateo, California, 94402 / US
02 / JOHNSON, Russell J.
c/o Sagimet Biosciences Inc.
155 Bovet Rd 303
San Mateo, California, 94402 / US
03 / ZAHARIA, Cristiana A.
c/o Sagimet Biosciences Inc.
155 Bovet Rd 303
San Mateo, California, 94402 / US
04 / CAI, Haiying
c/o Sagimet Biosciences Inc.
155 Bovet Rd 303
San Mateo, California, 94402 / US
05 / HU, Lily W.
c/o Sagimet Biosciences Inc.
155 Bovet Rd 303
San Mateo, California, 94402 / US
06 / DUKE, Greg
c/o Sagimet Biosciences Inc.
155 Bovet Rd 303
San Mateo, California, 94402 / US
07 / OHOL, Yamini
c/o Sagimet Biosciences Inc.
155 Bovet Rd 303
San Mateo, California, 94402 / US
08 / HEUER, Timothy
c/o Sagimet Biosciences Inc.
155 Bovet Rd 303
San Mateo, California, 94402 / US
09 / O'FARRELL, Marie
c/o Sagimet Biosciences Inc.
155 Bovet Rd 303
San Mateo, California, 94402 / US
 [2022/04]
Former [2020/01]01 / WAGMAN, Allan S.
c/o 3-V BIOSCIENCES INC.
155 Bovet Rd. 303
San Mateo, California 94402 / US
02 / JOHNSON, Russell J.
c/o 3-V BIOSCIENCES INC.
155 Bovet Rd. 303
San Mateo, California 94402 / US
03 / ZAHARIA, Cristiana A.
c/o 3-V BIOSCIENCES INC.
155 Bovet Rd. 303
San Mateo, California 94402 / US
04 / CAI, Haiying
c/o 3-V BIOSCIENCES INC.
155 Bovet Rd. 303
San Mateo, California 94402 / US
05 / HU, Lily W.
c/o 3-V BIOSCIENCES INC.
155 Bovet Rd. 303
San Mateo, California 94402 / US
06 / DUKE, Greg
c/o 3-V BIOSCIENCES INC.
155 Bovet Rd. 303
San Mateo, California 94402 / US
07 / OHOL, Yamini
c/o 3-V BIOSCIENCES INC.
155 Bovet Rd. 303
San Mateo, California 94402 / US
08 / HEUER, Timothy
c/o 3-V BIOSCIENCES INC.
155 Bovet Rd. 303
San Mateo, California 94402 / US
09 / O'FARRELL, Marie
c/o 3-V BIOSCIENCES INC.
155 Bovet Rd. 303
San Mateo, California 94402 / US
Former [2016/46]01 / WAGMAN, Allan S.
c/o 3-V BIOSCIENCES INC.
1050 Hamilton Court
Menlo Park, California 94025 / US
02 / JOHNSON, Russell J.
c/o 3-V BIOSCIENCES INC.
1050 Hamilton Court
Menlo Park, California 94025 / US
03 / ZAHARIA, Cristiana A.
c/o 3-V BIOSCIENCES INC.
1050 Hamilton Court
Menlo Park, California 94025 / US
04 / CAI, Haiying
c/o 3-V BIOSCIENCES INC.
1050 Hamilton Court
Menlo Park, California 94025 / US
05 / HU, Lily W.
c/o 3-V BIOSCIENCES INC.
1050 Hamilton Court
Menlo Park, California 94025 / US
06 / DUKE, Greg
c/o 3-V BIOSCIENCES INC.
1050 Hamilton Court
Menlo Park, California 94025 / US
07 / OHOL, Yamini
c/o 3-V BIOSCIENCES INC.
1050 Hamilton Court
Menlo Park, California 94025 / US
08 / HEUER, Timothy
c/o 3-V BIOSCIENCES INC.
1050 Hamilton Court
Menlo Park, California 94025 / US
09 / O'FARRELL, Marie
c/o 3-V BIOSCIENCES INC.
1050 Hamilton Court
Menlo Park, California 94025 / US
Representative(s)Grund, Martin
Grund Intellectual Property Group
Patentanwälte und Solicitor PartG mbB
Steinsdorfstraße 2
80538 München / DE
[N/P]
Former [2022/10]Grund, Martin
Grund Intellectual Property Group
Patentanwalt und Solicitor PartG mbB
Postfach 44 05 16
80754 München / DE
Former [2016/46]Grund, Martin
Grund
Intellectual Property Group
Postfach 44 05 16
80754 München / DE
Application number, filing date15700939.007.01.2015
[2016/46]
WO2015US10459
Priority number, dateUS201461924520P07.01.2014         Original published format: US 201461924520 P
[2016/46]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015105860
Date:16.07.2015
Language:EN
[2015/28]
Type: A1 Application with search report 
No.:EP3092232
Date:16.11.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 16.07.2015 takes the place of the publication of the European patent application.
[2016/46]
Type: B1 Patent specification 
No.:EP3092232
Date:09.03.2022
Language:EN
[2022/10]
Search report(s)International search report - published on:EP16.07.2015
ClassificationIPC:C07D405/14, C07D401/10, C07D403/10, A61K31/4155, A61K31/454, A61P35/00, A61P31/12
[2016/46]
CPC:
C07D403/10 (EP,CN,IL,KR,RU,US); A61K31/337 (IL,KR); A61K31/4155 (IL,KR,RU,US);
A61K31/454 (IL,KR,RU,US); A61K31/704 (IL,KR); A61K45/06 (IL,KR,US);
A61P31/12 (EP,IL,RU); A61P31/14 (EP,IL); A61P31/16 (EP,IL,RU);
A61P31/18 (EP,IL); A61P31/20 (EP,IL); A61P31/22 (EP,IL);
A61P35/00 (EP,IL,RU); A61P35/02 (EP,IL); A61P37/02 (EP,IL);
A61P43/00 (EP,IL); C07D401/10 (EP,CN,IL,KR,RU,US); C07D405/14 (EP,CN,IL,KR,RU,US);
A61K2300/00 (IL,KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/46]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:HETEROCYCLISCHE MODULATOREN DER LIPIDSYNTHESE ZUR VERWENDUNG GEGEN KREBS UND VIRUSINFEKTIONEN[2016/46]
English:HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS FOR USE AGAINST CANCER AND VIRAL INFECTIONS[2016/46]
French:MODULATEURS HÉTÉROCYCLES DE LA SYNTHÈSE DES LIPIDES DESTINÉS À ÊTRE UTILISÉS CONTRE LE CANCER ET LES INFECTIONS VIRALES[2016/46]
Entry into regional phase02.08.2016National basic fee paid 
02.08.2016Designation fee(s) paid 
02.08.2016Examination fee paid 
Examination procedure02.08.2016Examination requested  [2016/46]
03.03.2017Amendment by applicant (claims and/or description)
11.05.2017Despatch of a communication from the examining division (Time limit: M06)
20.09.2017Reply to a communication from the examining division
14.12.2017Despatch of a communication from the examining division (Time limit: M06)
23.07.2018Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
02.10.2018Reply to a communication from the examining division
12.06.2019Despatch of a communication from the examining division (Time limit: M04)
09.10.2019Reply to a communication from the examining division
24.06.2020Cancellation of oral proceeding that was planned for 11.11.2020
11.11.2020Date of oral proceedings (cancelled)
21.01.2021Cancellation of oral proceeding that was planned for 26.01.2021
26.01.2021Date of oral proceedings (cancelled)
24.03.2021Communication of intention to grant the patent
05.07.2021Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
09.08.2021Communication of intention to grant the patent
17.12.2021Fee for grant paid
17.12.2021Fee for publishing/printing paid
17.12.2021Receipt of the translation of the claim(s)
Opposition(s)12.12.2022No opposition filed within time limit [2023/07]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
02.10.2018Request for further processing filed
02.10.2018Full payment received (date of receipt of payment)
Request granted
17.10.2018Decision despatched
Fees paidRenewal fee
27.01.2017Renewal fee patent year 03
29.01.2018Renewal fee patent year 04
28.01.2019Renewal fee patent year 05
27.01.2020Renewal fee patent year 06
27.01.2021Renewal fee patent year 07
27.01.2022Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL09.03.2022
AT09.03.2022
CZ09.03.2022
DK09.03.2022
EE09.03.2022
FI09.03.2022
HR09.03.2022
LT09.03.2022
LV09.03.2022
MC09.03.2022
NL09.03.2022
PL09.03.2022
RO09.03.2022
RS09.03.2022
SE09.03.2022
SI09.03.2022
SK09.03.2022
SM09.03.2022
BG09.06.2022
NO09.06.2022
GR10.06.2022
IS09.07.2022
PT11.07.2022
[2024/29]
Former [2023/10]AL09.03.2022
AT09.03.2022
CZ09.03.2022
DK09.03.2022
EE09.03.2022
FI09.03.2022
HR09.03.2022
LT09.03.2022
LV09.03.2022
NL09.03.2022
PL09.03.2022
RO09.03.2022
RS09.03.2022
SE09.03.2022
SI09.03.2022
SK09.03.2022
SM09.03.2022
BG09.06.2022
NO09.06.2022
GR10.06.2022
IS09.07.2022
PT11.07.2022
Former [2023/07]AL09.03.2022
AT09.03.2022
CZ09.03.2022
DK09.03.2022
EE09.03.2022
FI09.03.2022
HR09.03.2022
LT09.03.2022
LV09.03.2022
NL09.03.2022
PL09.03.2022
RO09.03.2022
RS09.03.2022
SE09.03.2022
SK09.03.2022
SM09.03.2022
BG09.06.2022
NO09.06.2022
GR10.06.2022
IS09.07.2022
PT11.07.2022
Former [2023/01]AL09.03.2022
AT09.03.2022
CZ09.03.2022
EE09.03.2022
FI09.03.2022
HR09.03.2022
LT09.03.2022
LV09.03.2022
NL09.03.2022
PL09.03.2022
RO09.03.2022
RS09.03.2022
SE09.03.2022
SK09.03.2022
SM09.03.2022
BG09.06.2022
NO09.06.2022
GR10.06.2022
IS09.07.2022
PT11.07.2022
Former [2022/51]AT09.03.2022
CZ09.03.2022
EE09.03.2022
FI09.03.2022
HR09.03.2022
LT09.03.2022
LV09.03.2022
NL09.03.2022
PL09.03.2022
RO09.03.2022
RS09.03.2022
SE09.03.2022
SK09.03.2022
SM09.03.2022
BG09.06.2022
NO09.06.2022
GR10.06.2022
IS09.07.2022
PT11.07.2022
Former [2022/50]AT09.03.2022
CZ09.03.2022
EE09.03.2022
FI09.03.2022
HR09.03.2022
LT09.03.2022
LV09.03.2022
NL09.03.2022
PL09.03.2022
RO09.03.2022
RS09.03.2022
SE09.03.2022
SK09.03.2022
SM09.03.2022
BG09.06.2022
NO09.06.2022
GR10.06.2022
PT11.07.2022
Former [2022/49]AT09.03.2022
CZ09.03.2022
EE09.03.2022
FI09.03.2022
HR09.03.2022
LT09.03.2022
LV09.03.2022
NL09.03.2022
RO09.03.2022
RS09.03.2022
SE09.03.2022
SK09.03.2022
SM09.03.2022
BG09.06.2022
NO09.06.2022
GR10.06.2022
PT11.07.2022
Former [2022/48]AT09.03.2022
CZ09.03.2022
EE09.03.2022
FI09.03.2022
HR09.03.2022
LT09.03.2022
LV09.03.2022
NL09.03.2022
RO09.03.2022
RS09.03.2022
SE09.03.2022
SM09.03.2022
BG09.06.2022
NO09.06.2022
GR10.06.2022
PT11.07.2022
Former [2022/47]AT09.03.2022
FI09.03.2022
HR09.03.2022
LT09.03.2022
LV09.03.2022
NL09.03.2022
RO09.03.2022
RS09.03.2022
SE09.03.2022
SM09.03.2022
BG09.06.2022
NO09.06.2022
GR10.06.2022
PT11.07.2022
Former [2022/44]FI09.03.2022
HR09.03.2022
LT09.03.2022
LV09.03.2022
NL09.03.2022
RS09.03.2022
SE09.03.2022
BG09.06.2022
NO09.06.2022
GR10.06.2022
Former [2022/39]FI09.03.2022
HR09.03.2022
LT09.03.2022
LV09.03.2022
RS09.03.2022
SE09.03.2022
BG09.06.2022
NO09.06.2022
GR10.06.2022
Former [2022/36]HR09.03.2022
LT09.03.2022
LV09.03.2022
RS09.03.2022
SE09.03.2022
BG09.06.2022
NO09.06.2022
GR10.06.2022
Former [2022/35]HR09.03.2022
LT09.03.2022
RS09.03.2022
SE09.03.2022
BG09.06.2022
NO09.06.2022
Former [2022/33]LT09.03.2022
NO09.06.2022
Cited inInternational search[A]WO2008075077  (ASTRAZENECA AB [SE], et al) [A] 1-29 * the whole document *;
 [A]WO2008075070  (ASTRAZENECA AB [SE], et al) [A] 1-29 * the whole document *;
 [A]WO2008075064  (ASTRAZENECA AB [SE], et al) [A] 1-29* the whole document *;
 [A]WO2012122391  (3 V BIOSCIENCES INC [US], et al) [A] 1-29 * the whole document *;
 [XPI]WO2014008197  (3 V BIOSCIENCES INC [US]) [XP] 1,2,5-7,9-11,14,16-19,22-25 * compounds 249, 277, 276 * * claims 43, 151-157 * * page 10, line 15 - line 26 * [I] 3,4,8,12,13,15,20,21,26-29
by applicantUS3625214
 US4789734
 US4897268
 US4906474
 US4925673
 US5075109
 US5811128
 US5814344
 US5820883
 US5853763
 US5928647
 US5942252
    - "IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry", PURE APPL. CHEM., (1976), vol. 45, pages 13 - 30
    - COMPENDIUM OF ORGANIC SYNTHETIC METHODS, (1971), vol. 1
    - COMPENDIUM OF ORGANIC SYNTHETIC METHODS, (1974), vol. 2
    - COMPENDIUM OF ORGANIC SYNTHETIC METHODS, (1977), vol. 3
    - COMPENDIUM OF ORGANIC SYNTHETIC METHODS, (1980), vol. 4
    - COMPENDIUM OF ORGANIC SYNTHETIC METHODS, (1984), vol. 5
    - COMPENDIUM OF ORGANIC SYNTHETIC METHODS, vol. 6
    - "Comprehensive Organic Synthesis", SELECTIVITY, STRATEGY & EFFICIENCY IN MODERN ORGANIC CHEMISTRY, (1993), vol. 9
    - Protecting Groups in Organic Synthesis
    - PAUL AV ET AL., NATURE, (1998), vol. 393, no. 6682, pages 280 - 284
    - HUANG H ET AL., BIOCHEMISTRY, (2001), vol. 40, no. 27, pages 8055 - 8064
    - GERBER K; WIMMER E; PAUL AV, J VIROL, (2001), vol. 75, no. 22, pages 10979 - 10990
    - ROSSMANN M ET AL., NATURE, (1985), vol. 317, no. 6033, pages 145 - 53
    - SMITH T ET AL., SCIENCE, (1986), vol. 233, no. 4770, pages 1286 - 93
    - FLAVIN, R. ET AL., FUTURE ONCOLOGY, (2010), vol. 6, no. 4, pages 551 - 562
    - ORITA, H. ET AL., CLINICAL CANCER RESEARCH., (2007), vol. 13, no. 23, pages 7139 - 7145
    - PUIG, T. ET AL., BREAST CANCER RESEARCH, (2011), vol. 13, no. 6, page R131
    - BROWNE, CD., THE FASEB JOURNAL, (2006), vol. 20, no. 12, pages 2027 - 2035
    - CHAKRAVARTHY, M. V. ET AL., CELL METABOLISM, (2005), vol. 1, pages 309 - 322
    - WU, M. ET AL., PNAS, (2011), vol. 108, no. 13, pages 5378 - 5383
    - "Liposomes", G. GREGORIADIS, Drug Carriers in Biology and Medicine, ACADEMIC PRESS, (1979), page 2
    - JEIN, TIPS, (1998), vol. 19, pages 155 - 157
    - REMINGTON, The Science and Practice of Pharmacy, LIPPINCOTT WILLIAMS & WILKINS
    - TERESA, P. ET AL., CLIN. CANCER RES., (2009), vol. 15, no. 24, pages 7608 - 7615
    - CHUNG C.C. ET AL., ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, (2008), vol. 6, no. 3, pages 361 - 374
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.